

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

**COMPLETION OF DISCLOSEABLE TRANSACTION  
IN RELATION TO A SHARE BUY-BACK TRANSACTION  
OF A NON-WHOLLY OWNED SUBSIDIARY**

Reference is made to the announcement dated 31 March 2023 (the “**Announcement**”) issued by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) regarding Changchun Extrawell, a 73.11% indirect non-wholly owned subsidiary of the Company, entered into the Share Buy-Back Agreement with the Vendor to buy back for cancellation 9.14% of total issued share capital of Changchun Extrawell. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the Conditions have been fulfilled and the Completion of Share Buy-Back and Share Cancellation has been taken place on 19 June 2023. Immediately upon Completion and as at the date of this announcement, the total number of issued shares of Changchun Extrawell has reduced from 50,000,000 shares to 45,430,000 shares, and as a result of Share Cancellation its registered capital has reduced from RMB50,000,000 to RMB45,430,000. Accordingly, the shareholding interest of the Group in Changchun Extrawell is increased from 73.11% to 80.46%. Changchun Extrawell remains an indirect non-wholly owned subsidiary of the Group and the financial results (including earnings, assets and liabilities) of Changchun Extrawell will be consolidated into the financial statements of the Group.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 19 June 2023

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Guo Yi.*

\* *For identification purpose only*